Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

NCT05254171 is registered in ClinicalTrials.gov with Panbela Therapeutics, Inc. as lead sponsor.

NCT NCT05254171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05254171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Panbela Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 8, 2022
Completion date
January 1, 2027
Enrollment
600 (estimated)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer metastatic, pancreatic cancer stage iv, pancreatic ductal adenocarcinoma